Efectividad de los probioticos como estrategia terapéutica para modificar la micro-biota intestinal en pacientes adultos obesos
Artículo de revisión
Abstract
Introduction: Obesity is considered a global epidemic that leads to the evolution of metabolism. Obesity has been related to intestinal microbiota examinations, which is why it becomes an important objective for the management of this pathology, probiotics have been highlighted as an alternative to regulate the composition of the microbiota in obese people, since these have been described as live microorganisms that, when administered in adequate amounts, obtained a benefit for the health of the host. Objective: To review the available evidence about the efficacy of probiotics as a therapeutic strategy to modulate the intestinal microbiota in obese adult patients. Methodology: A bibliographic search of articles included in relevant databases such as PubMed, Taylor & Francis, Springer, Cochrane and Scielo, 75% of the articles reviewed corresponding to the period 2017-2022. Results: After carrying out the bibliographic review, the pathogenic mechanisms of obesity were analyzed, which seek to increase the number of Bifidobacterium spp. and lactic acid bars responsible for producing short-chain fatty acids (SCFA) and thus modifying the microbiota of obese patients. In the study of probiotics with an impact on the microbiota of this group of patients, the administration has been related to different strains of bacteria (L.gasseri SBT2055, L.gasseri BNR17, Lactobacillus.rhamnosus.ATCC.53103,.L.plantarum TENSIA, Lactobacillus spp..Puritan's.Pride, Lactobacillus.acidophilusLa5, Bifidobacterium.lactis Bb12.y L.casei DN001) to weight loss, however these studies were inconclusive. Conclusions: Probiotics allow modulating the functions of the endogenous microbiota, specifically the strains of Bifidobacterium spp. and Lactobacillus spp. since it influences body weight by improving energy metabolism and lipolysis, even when the results of most studies are not uniform or conclusive.
References
Rexford S A. Obesity epidemiology, Pathogenesis, and Treatment. A multidisciplinary Approach. Toronto, New Jersey: 2021; 2014. 20–20 p.
Cheung L, Hu F. Adult Obesity, A Global look at Rising Obesity Rates. HARVART TH CHAN [Internet]. [cited 2022 Oct 3]; Available from: https://www.hsph.harvard.edu/obesity-prevention-source/obesity-trends-original/obesity-rates-worldwide/
Ritchie H, Roser M. Obesity. OurWorldInData [Internet]. 2017 [cited 2022 Oct 3];1–18. Available from: https://ourworldindata.org/obesity.
Sbraccia P, Finer N. Obesity pathogenesis, Diagnosis and Treatment. Lenczi A, Jannini E, editors. Rome, Italy: 2019; 2019. 2–26 p.
Daniali M, Nikfar S, Abdollahi M. A brief overview on the use of probiotics to treat overweight and obese patients. Expert Rev Endocrinol Metab. 2020 Jan;15(1):1-4. doi: 10.1080/17446651.2020.1719068. Epub 2020 Jan 28. PMID: 31990591.
Instituto Nacional de Salud Publica, Encuesta Nacional de Salud y Nutrición. 2018; Available from: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf. https://www.tandfonline.com/doi/full/10.1080/19490976.2018.1465157
Melese Linger Endalifer, Gedefaw Diress, "Epidemiology, Predisposing Factors, Biomarkers, and Pre-vention Mechanism of Obesity: A Systematic Review", Journal of Obesity, vol. 2020, Article ID 6134362, 2020. https://doi.org/10.1155/2020/6134362.
Michael W Schwartz, Randy J Seeley, Lori M Zeltser, Adam Drewnowski, Eric Ravussin, Leanne M Redman, Rudolph L Leibel, Obesity Pathogenesis: An Endocrine Society Scientific State-ment, Endocrine Reviews, Volume 38, Issue 4, 1 August 2017, Pages 267–296, https://doi.org/10.1210/er.2017-00111.
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018 Jan 2;71(1):69-84. doi: 10.1016/j.jacc.2017.11.011. PMID: 29301630; PMCID: PMC7958889.
Gjermeni E, Kirstein AS, Kolbig F, Kirchhof M, Bundalian L, Katzmann JL, Laufs U, Blüher M, Garten A, Le Duc D. Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. Biomolecules. 2021 Sep 29;11(10):1426. doi: 10.3390/biom11101426. PMID: 34680059; PMCID: PMC8533625.
Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017 Jan 19;376(3):254-266. doi: 10.1056/NEJMra1514009. PMID: 28099824.
Suárez-Carmona Walter, Sánchez-Oliver Antonio Jesús, González-Jurado José Antonio. Fisiopatolo-gía de la obesidad: Perspectiva actual. Rev. chil. nutr. [Internet]. 2017 [citado 2022 Nov 16] ; 44( 3 ): 226-233. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75182017000300226&lng=es. http://dx.doi.org/10.4067/s0717-75182017000300226.
Vettor, R., Conci, S. Obesity Pathogenesis. In: Sbraccia, P., Finer, N. (eds) Obesity. Endocrinolo-gy.2019; Springer, Cham. https://doi.org/10.1007/978-3-319-46933-1_14.
Alizon S, Sofonea MT. SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. J Evol Biol. 2021 Dec;34(12):1867-1877. doi: 10.1111/jeb.13896. Epub 2021 Jul 17. PMID: 34196431; PMCID: PMC8447366.
Schütz F, Figueiredo-Braga M, Barata P, Cruz-Martins N. Obesity and gut microbiome: review of potential role of probiotics. Porto Biomed J. 2021 Jan 18;6(1):e111. doi: 10.1097/j.pbj.0000000000000111. PMID: 33490703; PMCID: PMC7817278.
Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A; on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut mi-crobiota: a new path to treat obesity. Int J Obes Suppl. 2019 Apr;9(1):10-19. doi: 10.1038/s41367-019-0011-7. Epub 2019 Apr 12. PMID: 31391921; PMCID: PMC6683132.
Gill VJS, Soni S, Shringarpure M, Anusheel, Bhardwaj S, Yadav NK, Patel A, Patel A. Gut Micro-biota Interventions for the Management of Obesity: A Literature Review. Cureus. 2022 Sep 19;14(9):e29317. doi: 10.7759/cureus.29317. PMID: 36161997; PMCID: PMC9484223.
Aoun A, Darwish F, Hamod N. The Influence of the Gut Microbiome on Obesity in Adults and the Role of Probiotics, Prebiotics, and Synbiotics for Weight Loss. Prev Nutr Food Sci. 2020 Jun 30;25(2):113-123. doi: 10.3746/pnf.2020.25.2.113. PMID: 32676461; PMCID: PMC7333005.
Laia Fontané, David Benaiges, Albert Goday, Gemma Llauradó, Juan Pedro-Botet. Influencia de la microbiota y de los probióticos en la obesidad. Clínica e Investigación en Arteriosclerosis. Volumen 30, Issue 6, 2018. Pages 271-279. ISSN 0214-9168. https://doi.org/10.1016/j.arteri.2018.03.004.
Wici?ski M, G?balski J, Go??biewski J, Malinowski B. Probiotics for the Treatment of Overweight and Obesity in Humans-A Review of Clinical Trials. Microorganisms. 2020 Jul 29;8(8):1148. doi: 10.3390/microorganisms8081148. PMID: 32751306; PMCID: PMC7465252.
Tomé-Castro XM, Rodriguez-Arrastia M, Cardona D, Rueda-Ruzafa L, Molina-Torres G, Roman P. Probiotics as a therapeutic strategy in obesity and overweight: a systematic review. Benef Microbes. 2021 Feb 24;12(1):5-15. doi: 10.3920/BM2020.0111. Epub 2021 Jan 17. PMID: 33459204.
Michael D, et al. “A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being.” Scientific reports vol. 10,1 4183. 6 Mar. 2020, doi:10.1038/s41598-020-60991-7.
Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, Aiello V, Romano B, De Lorenzo A, Izzo AA, Capasso R. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients. 2019 Nov 7;11(11):2690. doi: 10.3390/nu11112690. PMID: 31703257; PMCID: PMC6893459.
Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci. 2016 Jun 13;17(6):928. doi: 10.3390/ijms17060928. PMID: 27304953; PMCID: PMC4926461.
Hijova E. Probiotics and prebiotics, targeting obesity with functional foods. Bratisl Lek Listy. 2021;122(9):647-652. doi: 10.4149/BLL_2021_104. PMID: 34463111.
Cerdó T, García-Santos JA, G Bermúdez M, Campoy C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients. 2019 Mar 15;11(3):635. doi: 10.3390/nu11030635. PMID: 30875987; PMCID: PMC6470608.
Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, Prebiotics, Syn-biotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives. Curr Obes Rep. 2020 Sep;9(3):179-192. doi: 10.1007/s13679-020-00379-w. PMID: 32472285.
Agerholm-Larsen L, Raben A, Haulrik N, Hansen AS, Manders M, Astrup A. Effect of 8 week in-take of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr. 2000 Apr;54(4):288-97. doi: 10.1038/sj.ejcn.1600937. PMID: 10745279.
Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010 Jun;64(6):636-43. doi: 10.1038/ejcn.2010.19. Epub 2010 Mar 10. PMID: 20216555.
Jung SP, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, Kim JY. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013 Mar;34(2):80-9. doi: 10.4082/kjfm.2013.34.2.80. Epub 2013 Mar 20. PMID: 23560206; PMCID: PMC3611107.
Larsen N, Vogensen FK, Gøbel RJ, Michaelsen KF, Forssten SD, Lahtinen SJ, Jakobsen M. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin Nutr. 2013. Dec;32(6):935-40. doi: 10.1016/j.clnu.2013.02.007. Epub 2013 Mar 4. PMID: 23510724.
Omar JM, Chan YM, Jones ML, Prakash S, Jones PJH. Lactobacillus fermentum and Lactobacillus amylovorus as probiotics alter body adiposity and gut micro?ora in healthy persons. J Funct Foods. 2019;5.
Sharafedtinov KK, Plotnikova OA, Alexeeva RI, Sentsova TB, Songisepp E, Stsepetova J, et al. Hypocaloric diet supple- mented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients–a ran- domized double-blind placebo-controlled pilot study. Nutr J. 2018;12:138.
Brahe LK, Le Chatelier E, Prifti E, Pons N, Kennedy S, Blædel T, et al. Dietary modulation of the gut microbiota–a randomi- sed controlled trial in obese posmenopausal women. Br J Nutr. 2019;114:406---17.
Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consump-tion of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabe-tes mellitus. Lipids Health Dis 2012; 11:29.
Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr 2010; 103(12):1778-1783.
Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probi-otic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012; 28(5):539-543.
Agerholm-Larsen L, Raben A, Haulrik N, Hansen AS, Manders M, Astrup A. Effect of 8 week in-take of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 2000; 54(4):288-297.
Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akay Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a random-ized controlled trial. Eur J Clin Nutr 2010; 64(6):636- 643.
Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M. Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic sub-jects. Lipids Health Dis 2014; 13:36.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is a human-readable summary of (and not a substitute for) the license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
